Prevalence and prognostic impact of hepatopulmonary syndrome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective cohort study.
10.1097/CM9.0000000000002034
- Author:
He ZHAO
1
;
Jiaywei TSAUO
2
;
Xiaowu ZHANG
1
;
Huaiyuan MA
2
;
Ningna WENG
2
;
Zhengqiang YANG
1
;
Xiao LI
1
Author Information
1. Department of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
2. Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Carcinoma, Hepatocellular/pathology*;
Chemoembolization, Therapeutic;
Prospective Studies;
Liver Neoplasms/pathology*;
Prognosis;
Hepatopulmonary Syndrome/therapy*;
Prevalence;
Treatment Outcome;
Retrospective Studies
- From:
Chinese Medical Journal
2022;135(17):2043-2048
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:To determine the prevalence and prognostic impact of hepatopulmonary syndrome (HPS) in patients with unresectable hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE).
METHODS:Fifty-four patients with unresectable HCC undergoing TACE between December 2014 and December 2015 were prospectively screened for HPS and were followed up for a maximum of 2 years or until the end of this prospective study.
RESULTS:Nineteen of the 54 (35.2%) patients were considered to have HPS, including one (5.3%) with severe HPS, nine (47.4%) with moderate HPS, and nine (47.4%) with mild HPS. The median overall survival (OS) was 10.1 (95% confidence interval [CI], 3.9-16.3) months for patients with HPS and 15.1 (95% CI, 7.3-22.9) months for patients without HPS, which is not a significant difference ( P = 0.100). The median progression-free survival was also not significantly different between patients with and without HPS (5.2 [95% CI, 0-12.8] vs. 8.4 [95% CI, 3.6-13.1] months; P = 0.537). In the multivariable Cox regression analyses, carbon monoxide diffusing capacity (hazard ratio [HR] = 1.033 [95% CI, 1.003-1.064]; P = 0.028) and Child-Pugh class (HR = 1.815 [95% CI, 1.011-3.260]; P = 0.046) were identified to be the independent prognostic factors of OS.
CONCLUSION:Mild or moderate HPS is common in patients with unresectable HCC undergoing TACE, but it does not seem to have a significant prognostic impact.
